Compare PSTL & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PSTL | NMRA |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 554.6M | 554.0M |
| IPO Year | 2018 | 2023 |
| Metric | PSTL | NMRA |
|---|---|---|
| Price | $23.89 | $1.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $20.19 | $7.50 |
| AVG Volume (30 Days) | 282.8K | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.62% | N/A |
| EPS Growth | ★ 123.81 | 5.23 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $95,823,000.00 | N/A |
| Revenue This Year | $18.01 | N/A |
| Revenue Next Year | $11.38 | N/A |
| P/E Ratio | $214.86 | ★ N/A |
| Revenue Growth | ★ 25.47 | N/A |
| 52 Week Low | $13.17 | $0.66 |
| 52 Week High | $23.87 | $3.65 |
| Indicator | PSTL | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 69.61 | 42.53 |
| Support Level | $22.15 | $1.81 |
| Resistance Level | $23.87 | $1.90 |
| Average True Range (ATR) | 0.67 | 0.18 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 93.85 | 23.03 |
Postal Realty Trust Inc is an internally managed real estate investment trust. It is engaged in acquiring and managing properties mainly leased to the United States Postal Service, or the USPS, ranging from last-mile post offices to industrial facilities. The Trust's objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of its revenue is generated in the form of rental income.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.